Abstract: A system for ventilation, dehumidification, and cooling includes an outdoor unit dehumidifying and cooling introduced outside air; and an indoor unit connected to the outdoor unit to perform ventilation, in which the outdoor unit includes a dehumidification rotor, an evaporative cooler, an evaporative condenser, a ventilation damper, a heating unit, and a controller operating and stopping at least one of the dehumidification rotor, the evaporative cooler, the evaporative condenser, the ventilation damper, or the heating unit.

Abstract: The present invention relates to a Tie2 agonistic antibody that binds to an Ig3 Fn3 domain of human Tie2 or an antigen-binding fragment thereof, wherein by binding of the antibody, homodimer Tie2 can form a polygonal assembly so as to be clustered and activated.

Abstract: The present invention relates to a high-temperature superconducting rotating machine system equipped with a fixed type cryostat and a vaporized cryogen re-use cooling structure.

Abstract: The present disclosure provides a curable composition containing 20 to 30 wt % of boiled meat slices, 1 to 15 wt % of konjac, 30 to 50 wt % of glue, and 5 to 15 wt % of kelp, and a structure using the same.

Abstract: The present invention relates to a high-temperature superconducting rotating machine system equipped with a fixed type cryostat and a vaporized cryogen re-use cooling structure.

Abstract: The present invention relates to a deglycosylated LRG1 glycoprotein and a LRG1 glycoprotein variant, and a use thereof. The deglycosylated LRG1 glycoprotein and LRG1 glycoprotein variant of the present invention exhibit effects of angiogenesis, nerve growth and nerve regeneration that are superior to those of conventional LRG1 glycoproteins, and thus a composition containing thereof is effective in preventing and treating vascular erectile dysfunction, ischemic heart/brain/peripheral vascular diseases, diabetic vascular complications, neurogenic erectile dysfunction, diabetic neurologic complications, post-operative/post-traumatic peripheral nerve damage, ischemic diseases including neurodegenerative diseases, peripheral nerve diseases, erectile dysfunction and/or neurodegenerative diseases.

Abstract: Provided is a testing apparatus for an active current control-type non-contact superconductive exciter having a hybrid magnet installed therein, and a high-temperature superconductive rotating machine using same. Provided is principally characterized by having a hybrid magnet, in a module form, in which a permanent magnet, a DC electromagnet and an AC electromagnet are used together, wherein the hybrid magnet is set in a plurality along the circumferential direction of a ring-shaped iron stator, is formed to correspond to the outer side of a rotor, having a high-temperature superconductive tape (or a second-generation high-temperature superconductive wire), of a non-contact superconductive exciter, and thus enables a selected operation (charging, discharging and the like) before and after rotation of a driving motor.

Abstract: The present invention relates to a vertical axis wind turbine equipped with a high-temperature superconducting generator having a batch impregnation cooling structure. The vertical axis wind turbine is configured to allow the superconducting generator and accessory devices (a cooling system, a power conversion system, etc.) to be located under a turbine tower, whereas allowing only a rotary body with vertical blades to be located on the upper portion of the turbine tower, unlike a conventional horizontal axis wind turbine, thereby remarkably reducing a top-head weight of the wind turbine, greatly decreasing installation and maintenance costs, removing technical difficulties in large scale construction, and allowing a center of weight to move to a portion under the turbine tower so that if the vertical axis wind turbine is applied for floating offshore wind power generation, it advantageously ensures the miniaturization of a floating body and the stability of a floating posture.

Abstract: Disclosed are a novel interferon lambda variant produced through structure-based glycoengineering and a method of producing the same. The novel interferon lambda variant and the method of producing the same exhibit remarkably improved production and yield in mammalian cell lines using structural information-based glycoengineering even through conventional purification protocols, and exhibit significantly improved therapeutic properties such as stability, half-life, and fraction of functional proteins during treatment, compared to wild-type interferon lambda. In addition, the novel interferon lambda variant and the method of producing the same according to the present invention have higher antiviral activity and interferon-stimulated gene (ISG)-inducing activity than wild-type interferon lambda, and thus are useful for the prevention and treatment of immune-related diseases such as cancer and autoimmune diseases as well as various viral infections such as infection with SARS-CoV-2 (COVID-19).

Abstract: A system for ventilation, dehumidification, and cooling according to an exemplary embodiment in the present disclosure may include an outdoor unit dehumidifying and cooling introduced outside air; and an indoor unit connected to the outdoor unit to perform ventilation, in which the outdoor unit includes a dehumidification rotor, an evaporative cooler, an evaporative condenser, a ventilation damper, a heating unit, and a control module operating and stopping at least one of the dehumidification rotor, the evaporative cooler, the evaporative condenser, the ventilation damper, or the heating unit.

Abstract: The present disclosure provides a curable composition containing 20 to 30 wt % of boiled meat slices, 1 to 15 wt % of konjac, 30 to 50 wt % of glue, and 5 to 15 wt % of kelp, and a structure using the same.

Abstract: The present invention relates to a device for evaluating the performance of a superconductive coil for a high-temperature superconductive rotary machine and a method for evaluating the performance of a superconductive coil thereby. The technical gist of the present invention is to provide schemes for evaluating the stability of a superconductive coil and verifying the reliability thereof, to evaluate/confirm whether or not the same can be commercialized, and to evaluate/confirm the threshold current of a superconductive wire for manufacturing a superconductive coil or the upper limit of the operating current thereof, and is characterized in that the electromagnetic, thermal, and mechanical performances of a superconductive coil for a second-generation high-temperature superconductive rotary machine can be evaluated.

Abstract: The present invention relates to a VEGF-Grab protein-drug conjugate and a use thereof and, more particularly, to a conjugate of a fusion protein in which a VEGFR1 domain 2, a VEGFR1 domain 3, and an antibody fragment are connected and a drug, a pharmaceutical composition for prevention or treatment of cancer or angiogenesis-related disease, comprising the conjugate, and a method for prevention or treatment of cancer or angiogenesis-related disease. Serving as a multi-paratopic VEGF decoy receptor, the conjugate including a VEGF-Grab protein and a drug of the present invention can be used as a multi-purpose platform for treatment of cancer or angiogenesis-related disease.

Abstract: The present invention relates to a device for evaluating the performance of a superconductive coil for a high-temperature superconductive rotary machine and a method for evaluating the performance of a superconductive coil thereby. The technical gist of the present invention is to provide schemes for evaluating the stability of a superconductive coil and verifying the reliability thereof, to evaluate/confirm whether or not the same can be commercialized, and to evaluate/confirm the threshold current of a superconductive wire for manufacturing a superconductive coil or the upper limit of the operating current thereof, and is characterized in that the electromagnetic, thermal, and mechanical performances of a superconductive coil for a second-generation high-temperature superconductive rotary machine can be evaluated.

Abstract: The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

Abstract: The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component.

Abstract: The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.

Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.